In 2018, Mezquita et al. [33] developed a new potential blood-based biomarker, LIPI, which stratified baseline dNLR and LDH in patients with NSCLC under anti-PDL1 treatment according to survival outcomes. Here, CD274 is linked to non-small cell lung carcinoma.